Recursion Pharmaceuticals, Inc. RXRX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s accrued expenses?
- Recursion Pharmaceuticals, Inc. (RXRX) reported accrued expenses of $14.57M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s accrued expenses changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s accrued expenses decreased by 35.1% year-over-year, from $22.46M to $14.57M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s accrued expenses has grown at a 24.8% compound annual growth rate (CAGR), from $10.49M to $31.77M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.